This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar;14(3):128.

doi: 10.1038/nrrheum.2018.5. Epub 2018 Jan 25.

Osteoporosis: Romosozumab to rebuild the foundations of bone strength

Serge L Ferrari¹

Affiliations

PMID: 29367691
DOI: 10.1038/nrrheum.2018.5

Comment

Osteoporosis: Romosozumab to rebuild the foundations of bone strength

Serge L Ferrari. Nat Rev Rheumatol. 2018 Mar.

. 2018 Mar;14(3):128.

doi: 10.1038/nrrheum.2018.5. Epub 2018 Jan 25.

Author

Serge L Ferrari¹

Affiliation

¹ Service and Laboratory of Bone Diseases, Geneva University Hospital, 1205 Geneva, Switzerland.

PMID: 29367691
DOI: 10.1038/nrrheum.2018.5

No abstract available

PubMed Disclaimer

Comment on

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Saag KG, et al. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28892457 Clinical Trial.

Similar articles

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Saag KG, et al. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28892457 Clinical Trial.
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Saag KG, Petersen J, Grauer A. Saag KG, et al. N Engl J Med. 2018 Jan 11;378(2):195-196. doi: 10.1056/NEJMc1714810. N Engl J Med. 2018. PMID: 29320649 No abstract available.
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Lewis JR, Schousboe JT, Prince RL. Lewis JR, et al. N Engl J Med. 2018 Jan 11;378(2):194-5. doi: 10.1056/NEJMc1714810. N Engl J Med. 2018. PMID: 29322752 No abstract available.
Romosozumab for the treatment of osteoporosis.
Bandeira L, Lewiecki EM, Bilezikian JP. Bandeira L, et al. Expert Opin Biol Ther. 2017 Feb;17(2):255-263. doi: 10.1080/14712598.2017.1280455. Expert Opin Biol Ther. 2017. PMID: 28064540 Review.
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.
Asadipooya K, Weinstock A. Asadipooya K, et al. Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23. Arterioscler Thromb Vasc Biol. 2019. PMID: 31242037 Review.

See all similar articles

Cited by

First-line treatment of osteoporosis with osteoanabolic therapy: a new opportunity.
Aleksova J, Ebeling P. Aleksova J, et al. Intern Med J. 2025 Aug;55(8):1232-1241. doi: 10.1111/imj.70061. Epub 2025 Apr 9. Intern Med J. 2025. PMID: 40202097 Free PMC article. Review.
Skeletal changes during and after spaceflight.
Vico L, Hargens A. Vico L, et al. Nat Rev Rheumatol. 2018 Mar 21;14(4):229-245. doi: 10.1038/nrrheum.2018.37. Nat Rev Rheumatol. 2018. PMID: 29559713 Review.
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.
Hesse E, Schröder S, Brandt D, Pamperin J, Saito H, Taipaleenmäki H. Hesse E, et al. JCI Insight. 2019 Apr 9;5(9):e125543. doi: 10.1172/jci.insight.125543. JCI Insight. 2019. PMID: 30965315 Free PMC article.
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives.
Lim SY, Bolster MB. Lim SY, et al. Int J Womens Health. 2022 Dec 15;14:1733-1747. doi: 10.2147/IJWH.S315184. eCollection 2022. Int J Womens Health. 2022. PMID: 36544862 Free PMC article. Review.
Spatiotemporal Analysis of Osteoblast Morphology and Wnt Signal-Induced Osteoblast Reactivation during Bone Modeling in Vitro.
Tsuji N, Sakamoto T, Hoshi K, Hikita A. Tsuji N, et al. JBMR Plus. 2022 Oct 21;6(11):e10689. doi: 10.1002/jbm4.10689. eCollection 2022 Nov. JBMR Plus. 2022. PMID: 36398107 Free PMC article.

See all "Cited by" articles

References

1. Endocr Rev. 2012 Oct;33(5):747-83 - PubMed
1. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523 - PubMed
1. N Engl J Med. 2017 Oct 12;377(15):1417-1427 - PubMed
1. JAMA. 2016 Aug 16;316(7):722-33 - PubMed
1. Lancet. 2017 Sep 30;390(10102):1585-1594 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information